ABVX enters the week of August 12 with a striking divergence: the ORTEX short score has spiked sharply higher while the borrow market has moved in the opposite direction, loosening to its most accommodating level in months.
The short score tells the most urgent story. It jumped from 57.4 on August 3 to 68.2 on August 11 — a move of nearly 11 points in less than two weeks. That puts the score at its highest level in the available window and ranks ABIVAX in the 14th percentile for short score across the broader universe, meaning shorts are more active here than at roughly 86% of comparable names. The factor scores reinforce the skew: the days-to-cover rank sits in the 9th percentile and utilization rank in the 24th, both pointing to a positioning profile that leans bearish on a relative basis.
The borrow market, however, has moved the other way — and that contrast is worth naming. Availability has climbed to 152.6% of short interest, up from around 45–55% in early July, when the lending pool was tight enough to create meaningful friction for new shorts. That earlier tightness has unwound almost entirely. Cost to borrow has also eased, running at 1.71% — down from nearly 3% at the start of July — and has been broadly stable for the past two weeks. A short score rising while borrow conditions loosen is an unusual combination: it suggests the bearish signal is driven by price and momentum factors rather than by lend-driven squeeze pressure. The stock is down 10.5% over the past month to €110, and that price weakness is feeding the score.
The Street picture offers limited help for the bulls, and the analyst data here requires a clear caveat. The only available consensus figures date to October 2023 — nearly three years ago — and cannot be treated as current. What the factor scores do show is that EPS momentum ranks in the 16th percentile on a 30-day basis and the 23rd on 90 days, both weak readings, while the EPS surprise percentile sits at just 30. The forward EPS growth score (63rd percentile) is the one constructive note in the factor stack, suggesting analysts still model improvement — but the pace of that improvement is not moving the needle on near-term sentiment. Valuation multiples are difficult to interpret cleanly for a pre-profitability biotech: the price-to-book of 10.9x has eased from earlier peaks, and the negative PE and EV/EBITDA are structural rather than signalling anything new.
Institutional ownership adds some texture. Among the top holders, UBS Asset Management trimmed by 3.3 million shares as of the March quarter, Darwin Global cut by 791,000, and Sofinnova Partners — a specialist biotech fund — reduced by 4.2 million shares as of early July. Against that, BlackRock added 1.4 million shares through July and Bank of America added 1.8 million in the June quarter. The net picture is of specialist holders lightening and generalist or index-adjacent flows partially replacing them, which is not an unusual pattern for a biotech that has underperformed.
Insider activity is modest in the recent window. Chairman Sylvie Grégoire sold 3,375 shares at €120.87 on July 15 — a relatively small disposal following a stock award earlier the same month. CEO Marc De Garidel has received a series of routine equity awards throughout 2026 with no open-market purchases logged. Neither pattern points to strong conviction buying from management at current levels.
The next scheduled event is a results announcement on September 21. The most recent comparable print, in May, produced a one-day move of +9.5% and held most of that gain over the following week. The March release moved -5.3% on the day and extended to -7.5% over five sessions. Peer performance this week has been mixed: GMAB gained 6.1% and PRAX surged 19.5%, while HRTX collapsed 36.7% — a reminder of how binary biotech catalysts can be. With the short score at a recent high but borrow conditions loose, the setup into September's event will be worth monitoring as availability and cost-to-borrow trends either confirm or contradict the score's bearish read.
See the live data behind this article on ORTEX.
Open ABVX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
